Buy Butadion pills 150 mg 10 pcs pack
  • Buy Butadion pills 150 mg 10 pcs pack

Phenylbutazone

Obolensky OP
1950 Items
2019-09-19
Dosage form
Brand & Manufacturer
Package Size
$22.44
Quantity
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

NSAIDs from the group of pyrazolone derivatives. Butanedione has anti-inflammatory, analgesic and antipyretic effects due to inhibition of COX activity and a decrease in prostaglandin synthesis.

Indications

Inflammatory and degenerative diseases of the musculoskeletal system: rheumatoid, gouty, psoriatic arthritis, ankylosing spondylitis (Bechterew's disease), osteoarthritis, arthritis with SLE (as part of complex therapy).
Pain syndrome: bursitis, tendovaginitis, arthralgia, myalgia, neuralgia, toothache and headache (including migraine) pain, algomenorrhea, pain due to injuries, burns.
Feverish syndrome with colds and infectious diseases.
Designed for symptomatic therapy, reducing pain and inflammation at the time of use, does not affect the progression of the disease.

Composition

1 tablet contains:
Active ingredient: phenylbutazone - 150 mg.

Phenylbutazone is marketed under different brands and generic names, and comes in different dosage forms:

Brand nameManufacturerCountryDosage form
Butadion Obolensky OP Russia pills
Butadion Gedeon Richter Hungary ointment

No customer reviews for the moment.

Write your review

Write your review

Phenylbutazone

Dosage and Administration

Orally, on 0.2-0.4 g during or after meals 3-4 times a day.
Children aged 6 months - 0.01-0.1 g (depending on age) 3-4 times a day. The duration of therapy is 2-5 weeks or more.

Adverse reactions

On the part of the digestive system: dyspepsia, NSAID-gastropathy, abdominal pain, nausea, vomiting, heartburn, diarrhea or constipation; with long-term use in large doses - ulceration of the mucous membrane of the gastrointestinal tract, aphthous stomatitis, glossitis, erosive esophagitis, bleeding (gastrointestinal, gingival, hemorrhoidal), abnormal liver function.
From the side of the cardiovascular system: increased blood pressure, tachycardia.
From the nervous system: headache, dizziness, drowsiness, depression, agitation.
From the senses: hearing loss, tinnitus.
From the side of blood-forming organs: agranulocytosis, leukopenia, anemia, thrombocytopenia.
Allergic reactions: skin rash, itching, urticaria, bronchospasm, edematous syndrome, angioedema.
Other: increased sweating, uterine bleeding.

Contraindications

Hypersensitivity; complete or incomplete combination of bronchial asthma, recurrent nasal polyposis and paranasal sinuses and intolerance to ASA or other NSAIDs (including a history of);
Erosive and ulcerative lesions of the gastrointestinal tract in the acute stage (peptic ulcer and 12 duodenal ulcers, ulcerative colitis, peptic ulcer), bone marrow depression, decompensated CHF or pulmonary heart disease, severe hepatic and / or renal failure (CC less than 30 ml / min), the period after coronary artery bypass surgery;
progressive kidney disease, active liver disease, confirmed hyperkalemia,
pregnancy (III trimester), active gastrointestinal bleeding, inflammatory bowel disease.
Carefully. Hyperbilirubinemia, bronchial asthma, chronic heart failure, edema, hypertension, hemophilia, hypocoagulation, hepatic failure, chronic renal failure, hearing loss, pathologies of the vestibular apparatus, blood diseases, diabetes, SLE, polymyalgia rheumatica, temporal arteritis, ulcerative gastrointestinal disease, stomatitis, ischemic heart disease, cerebrovascular diseases, dyslipidemia / hyperlipidemia, peripheral artery disease, smoking, chronic renal failure (CK 30-60 ml / min), ulcerative lesions of the gastrointestinal tract in history, the presence of H. pylori infection,
old age, prolonged use of NSAIDs, alcoholism, severe somatic diseases, simultaneous administration of oral GCS (including prednisolone), anticoagulants (including warfarin), antiplatelet agents (including acetylsalicylic acid, clopidogrel), selective serotonin reuptake inhibitors (including citalopram, fluoxetine, paroxetine, sertraline),
pregnancy, lactation.

Drug interactions

It enhances the effect of indirect anticoagulants, antiplatelet agents, fibrinolytics, side effects of GCS and MKS, estrogens, morphine, PAS, penicillin, hypoglycemic effect of sulfonylurea derivatives.
Reduces the effectiveness of uricosuric, antihypertensive drugs and diuretics.
Increases blood concentration of drugs Li +, methotrexate.
Inductors of microsomal oxidation in the liver (phenytoin, ethanol, barbiturates, rifampicin, tricyclic antidepressants) increase the production of hydroxylated active metabolites.
Antacids and colestyramine reduce absorption.
Myelotoxic drugs increase the hematotoxicity of the drug.

Special instructions

During treatment, control of the pattern of peripheral blood and the functional state of the liver and kidneys is necessary.
If necessary, determine the 17-ketosteroids drug should be canceled 48 hours before the study.
During treatment, you should refrain from engaging in potentially hazardous activities that require increased attention and speed of mental and motor responses. To reduce the risk of adverse events from the gastrointestinal tract, use the minimum effective dose of the shortest possible course.

Overdosage

Symptoms: cyanosis of the tips of the fingers, lips, body skin, dizziness, headache, increased or decreased blood pressure, hyperventilation of the lungs, clouding of consciousness, in children - myoclonic convulsions, nausea, vomiting, pain in the abdomen, hemorrhage, impaired liver and kidney function.
Treatment: gastric lavage, the introduction of Activated charcoal, symptomatic therapy aimed at maintaining the vital functions of the body. Forced diuresis and hemodialysis are ineffective.

  • Brand name: Butadion
  • Active ingredient: Phenylbutazone
  • Dosage form: Pills
  • Manufacturer: Obolensky OP
  • Country of Origin: Russia

Studies and clinical trials of Phenylbutazone (Click to expand)

  1. Untoward effects of phenylbutazone (butazolidin)–A re-evaluation
  2. Phenylbutazone toxicity: Depression of erythropoiesis
  3. Studies concerning the relationship of phenylbutazone to pituitary-adrenal cortical function and metabolism of 17-hydroxycorticosteroids
  4. Results of a clinical trial of g-28315, a sulfoxide analog of phenylbutazone, as a uricosuric agent in gouty subjects
  5. Phenylbutazone as a therapeutic agent in rheumatic diseases: Its present status
  6. Histologic study of synovial tissue following oral and intra-articular administration of phenylbutazone
  7. Comparative bioassay of drugs in adjuvant-induced arthritis in rats: Flufenamic acid, mefenamic acid, and phenylbutazone
  8. Double-blind study of fenoprofen versus phenylbutazone in acute gouty arthritis
  9. Bioavailability of phenylbutazone from a new enteric-coated formulation with superior dissolution characteristics
  10. Plasma profiles following single, oral, and rectal doses of phenylbutazone in healthy volunteers
  11. Recurrent small bowel obstruction associated with phenylbutazone
  12. Gas chromatographic and high resolution mass spectrometric determination of phenylbutazone in blood
  13. Determination of phenylbutazone, tolbutamide and metabolites in plasma and urine using chemical ionization mass spectrometry
  14. ChemInform Abstract: Interaction of Phenylbutazone and Colchicine in Binding to Serum Albumin in Rheumatoid Therapy: 1H NMR Study
  15. Warfarin metabolites: Stereochemical aspects of protein binding and displacement by phenylbutazone
  16. Effect of supersaturation on the crystallization of phenylbutazone polymorphs
  17. Phenylbutazone liver injury: A clinical-pathologic survey of 23 cases and review of the literature
  18. Synthesis of 3 or 5[14C] 4-butyl-1, 2-diphenyl-3, 5-pyrazolidinedione (phenylbutazone)
  19. Evaluation of phenylbutazone and poly(amidoamine) dendrimers interactions by a combination of solubility, 2D-NOESY NMR, and isothermal titration calorimetry studies
  20. Physicochemical characterisation, drug polymer dissolution and in vitro evaluation of phenacetin and phenylbutazone solid dispersions with polyethylene glycol 8000
  21. Determination and thin-layer chromatography of phenylbutazone in the presence of decomposition products
  22. Ultraviolet spectrophotometric determination of phenylbutazone in biologic specimens
  23. Pharmacokinetic analysis of potentiating effect of phenylbutazone on anticoagulant action of warfarin in man
  24. Phenylbutazone-sodium warfarin binding using a fluorescent probe technique

8 other products in the same category:

arrow_upward